article

Drug Target Review – Issue #3 2015

Posted: 21 September 2015 | Drug Target Review

Included in this issue: Drug Development, Microfluidics, Proteomics, Ion Channels, GPCR, Imaging, Flow Cytometry, Enzymes

DTR Issue 3 2015

In Issue #3 2015 of Drug Target Review:

  • FOREWORD
    When 0.77% is greater than 1%: salutatory lessons from the Court of Appeal
    Jacob Gifford Head, Thomas More Chambers
  • DRUG DEVELOPMENT
    Immunogenicity: anticipating and avoiding issues for biopharmaceutical development
    Paul Chamberlain, NDA Advisory Board
  • MICROFLUIDICS
    Microfluidic technology: the next-generation drug discovery tool
    Kimberly Plevniak and Mei He, Kansas State University
  • IN-DEPTH FOCUS: PROTEOMICS
    With articles from David J. Britton and Pedro R. Cutillas, Barts Cancer Institute, and Manfred Raida, National University of Singapore
  • ION CHANNELS
    Small molecules versus biologics: the quest for the ideal Nav1.7 inhibitor
    Marzia Martina and Martin N. Perkins, National Research Council of Canada
  • GPCR
    Exploiting functional selectivity of GPCRs in drug development
    Niklas Larsson and Torben Østerlund, AstraZeneca
  • IN-DEPTH FOCUS: IMAGING
    Featuring articles from Dimitri Scholz and Jeremy C. Simpson, University College Dublin, University of Glasgow’s Rudi Marquez, plus Zuzana Flachbartova, University of Veterinary Medicine and Pharmacy. Q&A interview with Molecular Devices
  • FLOW CYTOMETRY
    Flow cytometry: not just a box in a lab
    Rachael Walker, Babraham Institute
  • ENZYMES
    Ubiquitin-specific proteases as druggable targets
    Mindy I. Davis and Anton Simeonov, National Institutes of Health

Issue #3 2015 is restricted to logged-in members. Login or subscribe free to read it.


Related topics
,

Send this to a friend